Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial
Importance: Muscle-related statin intolerance is reported by 5% to 20% of patients. <br/>Objective: To identify patients with muscle symptoms confirmed by statin rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe and evolocumab. <br/> Design, Setting,...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Udgivet: |
American Medical Association
2016
|